A Randomized Blinded, LT Dose-Ranging Study to Assess the Immunogenicity and Safety of Different Doses of LT Adjuvant Patch Administered in Conjunction With Different Doses of Inactivated Influenza A/H5N1 Vaccine in Healthy Adults.

Trial Profile

A Randomized Blinded, LT Dose-Ranging Study to Assess the Immunogenicity and Safety of Different Doses of LT Adjuvant Patch Administered in Conjunction With Different Doses of Inactivated Influenza A/H5N1 Vaccine in Healthy Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 May 2014

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; Heat-labile enterotoxin E coli
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Intercell USA
  • Most Recent Events

    • 13 Mar 2012 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Status changed from active, no longer recruiting to completed, according to an Intercell media release.
    • 02 Jul 2010 Results reported in an Intercell media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top